All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
June 1, 2026
47% of the patients in this study had complete response (CR) on all oral regimen of decitabine–cedazuridine 5 days every 28 days plus venetoclax 400mg daily.